---
title: "Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296393818.md"
description: "CMB International Securities analyst Jill Wu reaffirmed a Buy rating on Kelun-Biotech, raising the target price from HK$507.11 to HK$642.29. The upgrade reflects strong momentum in sac-TMT commercialization, robust H1 revenue growth, and successful Phase 3 trial results across multiple tumor types. Increased confidence in global trials and MSD-led programs drove the DCF-derived valuation increase."
datetime: "2026-08-19T17:25:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296393818.md)
  - [en](https://longbridge.com/en/news/296393818.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296393818.md)
generator: "portal-rs"
---

# Kelun-Biotech: Buy Rating Reaffirmed as Strong sac-TMT Momentum Drives Target Price Increase from HK$507.11 to HK$642.29

CMB International Securities analyst Jill Wu maintained a Buy rating on Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H today and set a price target of HK$642.29.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Jill Wu has given his Buy rating due to a combination of factors tied to Kelun-Biotech’s strong operating and clinical momentum. The company delivered faster-than-expected commercialization of sac-TMT in China, with robust first-half revenue growth, a profitable swing supported by NRDL-driven uptake, and additional indications likely entering reimbursement later this year to sustain volume expansion.

Jill Wu’s rating is based on sac-TMT’s increasingly validated global and domestic profile, including multiple successful Phase 3 results that support blockbuster potential and broaden its use across NSCLC, TNBC and other tumors. Reflecting higher confidence in these global trials and MSD-led development and combination programs, she lifted her DCF-derived target price from HK$507.11 to HK$642.29, reinforcing a favorable risk-reward and justifying the Buy recommendation.

### Related Stocks

- [06990.HK](https://longbridge.com/en/quote/06990.HK.md)
- [002422.CN](https://longbridge.com/en/quote/002422.CN.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)

## Related News & Research

- [BMO Capital Sticks to Their Buy Rating for Merck & Company (MRK)](https://longbridge.com/en/news/296482637.md)
- [Key facts: Merck (MRK) up on vaccine; policy may hit M-M-R II, ProQuad](https://longbridge.com/en/news/296749142.md)
- [Merck & Co., Inc. $MRK Shares Purchased by Russell Investments Group Ltd.](https://longbridge.com/en/news/296761195.md)
- [Crew Capital Management Ltd Acquires 7,742 Shares of Merck & Co., Inc. $MRK](https://longbridge.com/en/news/296582210.md)
- [Narwhal Capital Management Reduces Holdings in Merck & Co., Inc. $MRK](https://longbridge.com/en/news/296329835.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**